



# MEDICARE FORM

## Leqvio® (inclisiran) Medication Precertification Request

Page 1 of 2

(All fields must be completed and legible for precertification review.)

For Medicare Advantage Part B:  
Phone: **1-866-503-0857** (TTY: **711**)  
FAX: **1-844-268-7263**

For other lines of business:  
Please use other form.

**Note: For MAPD plans, Leqvio is non-preferred. Repatha is preferred through the Part D benefit. Leqvio is not subject to step therapy on MA only plans.**

Please indicate:  Start of treatment: start date \_\_\_\_ / \_\_\_\_ / \_\_\_\_  Continuation of therapy, date of last treatment \_\_\_\_ / \_\_\_\_ / \_\_\_\_

Precertification Requested By: \_\_\_\_\_ Phone: \_\_\_\_\_ Fax: \_\_\_\_\_

### A. PATIENT INFORMATION

First Name:		Last Name:		DOB:	
Address:			City:		State: ZIP:
Home Phone:		Work Phone:		Cell Phone: Email:	
Patient Current Weight: ____ lbs or ____ kgs		Patient Height: ____ inches or ____ cms		Allergies:	

### B. INSURANCE INFORMATION

Aetna Member ID #: _____		Does patient have other coverage? <input type="checkbox"/> Yes <input type="checkbox"/> No	
Group #: _____		If yes, provide ID#: _____ Carrier Name: _____	
Insured: _____		Insured: _____	
Medicare: <input type="checkbox"/> Yes <input type="checkbox"/> No If yes, provide ID #: _____		Medicaid: <input type="checkbox"/> Yes <input type="checkbox"/> No If yes, provide ID #: _____	

### C. PRESCRIBER INFORMATION

First Name:		Last Name:		(Check One): <input type="checkbox"/> M.D. <input type="checkbox"/> D.O. <input type="checkbox"/> N.P. <input type="checkbox"/> P.A.	
Address:			City:		State: ZIP:
Phone:		Fax:		St Lic #: NPI #: DEA #: UPIN:	
Provider Email:		Office Contact Name:		Phone:	

Specialty (Check one):  Cardiologist  Other: \_\_\_\_\_

### D. DISPENSING PROVIDER/ADMINISTRATION INFORMATION

<b>Place of Administration:</b> <input type="checkbox"/> Self-administered <input type="checkbox"/> Physician's Office <input type="checkbox"/> Outpatient Infusion Center Phone: _____ Center Name: _____ <input type="checkbox"/> Home Infusion Center Phone: _____ Agency Name: _____ <input type="checkbox"/> Administration code(s) (CPT): _____ Address: _____ City: _____ State: _____ ZIP: _____ Phone: _____ Fax: _____ <b>TIN:</b> _____ <b>PIN:</b> _____ <b>NPI:</b> _____		<b>Dispensing Provider/Pharmacy: Patient Selected choice</b> <input type="checkbox"/> Physician's Office <input type="checkbox"/> Retail Pharmacy <input type="checkbox"/> Specialty Pharmacy <input type="checkbox"/> Other Name: _____ Address: _____ City: _____ State: _____ ZIP: _____ Phone: _____ Fax: _____ <b>TIN:</b> _____ <b>PIN:</b> _____ <b>NPI:</b> _____	
---	--	---	--

### E. PRODUCT INFORMATION

Request is for: Leqvio (inclisiran) Dose: \_\_\_\_\_ Frequency: \_\_\_\_\_ HCPCS Code: \_\_\_\_\_

### F. DIAGNOSIS INFORMATION - Please indicate primary ICD code and specify any other where applicable.

Primary ICD Code: \_\_\_\_\_ Secondary ICD Code: \_\_\_\_\_ Other ICD Code: \_\_\_\_\_

### G. CLINICAL INFORMATION - Required clinical information must be completed in its entirety for all precertification requests.

Please indicate the current LDL-C level in mg/dL: \_\_\_\_\_

**For Initiation Requests (clinical documentation required):**

**Note: Leqvio is non-preferred on MAPD plans. Repatha is preferred through the Part D benefit. Leqvio is not subject to step therapy on MA only plans.**

Yes  No Has the patient had prior therapy with Leqvio (inclisiran) within the last 365 days?

Yes  No Has the patient had a trial and failure, intolerance, or contraindication to Repatha (evolocumab)?

Please explain if there are any other medical reason(s) that the patient cannot use Repatha (evolocumab) when indicated for the patient's diagnosis.

\_\_\_\_\_

Yes  No Will the patient continue to receive concomitant statin therapy?  
 Yes  No Does the patient have intolerance or contraindication to high-intensity statin therapy?

Please indicate the prior therapy the patient has previously received (select all that applies to the patient):

The patient is receiving a high-intensity statin dose daily, such as rosuvastatin (Crestor) 20 mg daily or atorvastatin (Lipitor) 40 mg daily  
 Please indicate the start date: \_\_\_\_ / \_\_\_\_ / \_\_\_\_  
 Yes  No Has the patient received this dose for at least 3 months?  
 Yes  No Was the patient unable to tolerate a high-intensity statin due to adverse effects?

Continued on next page



# MEDICARE FORM

## Leqvio® (inclisiran) Medication Precertification Request

Page 2 of 2

(All fields must be completed and legible for precertification review.)

For Medicare Advantage Part B:  
Phone: **1-866-503-0857** (TTY: **711**)  
FAX: **1-844-268-7263**

For other lines of business:  
Please use other form.

Note: For MAPD plans, Leqvio is non-preferred. Repatha is preferred through the Part D benefit. Leqvio is not subject to step therapy on MA only plans.

Patient First Name	Patient Last Name	Patient Phone	Patient DOB
--------------------	-------------------	---------------	-------------

### G. CLINICAL INFORMATION (continued) – Required clinical information must be completed in its entirety for all precertification requests.

#### For Initiation Requests (clinical documentation required) - continued:

- The patient is receiving a moderate-intensity statin dose daily, such as atorvastatin (Lipitor) 20 mg or equivalent
  - ↳ Please indicate the start date: \_\_\_\_ / \_\_\_\_ / \_\_\_\_
  - Yes  No Has the patient received this dose for at least 3 months?
- The patient has intolerance to a high-intensity statin therapy
  - ↳  Yes  No Did the patient score a 7 or higher on the Statin-Associated Muscle Symptom Clinical Index (SAMS-CI)?
  - Yes  No Did the patient experience a statin-associated increase in creatine kinase (CK) level of greater than or equal to 10 times the upper limit of normal (ULN) during previous treatment with a statin?
- The patient has contraindication to a high-intensity statin therapy
  - ↳ Please indicate which of the following applies to the patient:
    - Active liver disease, including unexplained persistent elevations in hepatic transaminase levels (e.g., ALT greater than or equal to 3 times the upper limit of normal)
    - Currently pregnant  Planning pregnancy  Breastfeeding  None of the above

#### Clinical atherosclerotic cardiovascular disease (ASCVD)

Please indicate which of the following manifestations of clinical atherosclerotic cardiovascular disease (ASCVD) the patient has experienced:

- Acute coronary syndrome
- Coronary Artery Calcium (CAC) score of greater than or equal to 1000
- Coronary or other arterial revascularization procedure (e.g., percutaneous coronary intervention [PCI], coronary artery bypass graft [CABG] surgery)
- Myocardial infarction
- Non-cardiac peripheral arterial disease (PAD) of presumed atherosclerotic origin (e.g., carotid artery stenosis, lower extremity PAD)
- Obstructive coronary artery disease (defined as fifty percent or greater stenosis on cardiac computed tomography angiogram or catheterization)
- Stable or unstable angina
- Stroke of presumed atherosclerotic origin
- Transient ischemic attack (TIA)
- Other

#### Heterozygous familial hypercholesterolemia (HeFH)

- Yes  No Does the patient possess an LDL-receptor mutation, familial defective apo B-100 or a PCSK9 mutation?
  - ↳ Please indicate the patient's untreated (before any lipid-lowering therapy) LDL-C level in mg/dL: \_\_\_\_
  - Please select which of the following applies to the patient:
    - Family history of myocardial infarction (MI) at less than 60 years of age in a first degree relative or less than 50 years of age in a second degree relative
    - Family history of total cholesterol (TC) greater than 290 mg/dL in a first/second degree relative
    - Presence of tendon xanthoma(s) in the patient or first/second-degree relative
    - None of the above- the patient does not meet any of the criteria listed above

#### For Continuation Requests (clinical documentation required):

- Yes  No Has the patient achieved or maintained an LDL-C reduction (e.g., LDL-C is now at goal, robust lowering of LDL-C) as the result of the requested medication therapy?
- Please indicate which of the following applies to the patient:
  - The patient is currently receiving concomitant statin therapy
    - ↳  Yes  No Will the patient continue to receive concomitant statin therapy?
  - The patient has intolerance to a high-intensity statin therapy
    - ↳  Yes  No Did the patient score a 7 or higher on the Statin-Associated Muscle Symptom Clinical Index (SAMS-CI)?
    - Yes  No Did the patient experience a statin-associated increase in creatine kinase (CK) level of greater than or equal to 10 times the upper limit of normal (ULN) during previous treatment with a statin?
  - The patient has contraindication to a high-intensity statin therapy
    - ↳ Please indicate which of the following applies to the patient:
      - Active liver disease, including unexplained persistent elevations in hepatic transaminase levels (e.g., ALT greater than or equal to 3 times upper limit of normal)
      - Currently pregnant  Planning pregnancy  Breastfeeding  None of the above

### H. ACKNOWLEDGEMENT

Request Completed By (Signature Required): \_\_\_\_\_ Date: \_\_\_\_ / \_\_\_\_ / \_\_\_\_

Any person who knowingly files a request for authorization of coverage of a medical procedure or service with the intent to injure, defraud or deceive any insurance company by providing materially false information or conceals material information for the purpose of misleading, commits a fraudulent insurance act, which is a crime and subjects such person to criminal and civil penalties.

The plan may request additional information or clarification, if needed, to evaluate requests.